Lund­beck, Ot­su­ka take the lat­est hit on Alzheimer’s as PhI­II drug flops

Den­mark’s Lund­beck has just racked up the lat­est R&D dis­as­ter in Alzheimer’s, re­port­ing that its first Phase III study for its 5-HT6 ag­o­nist idalopir­dine failed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER